The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > REGULATORY
REGULATORY
- Japan Research Group to Wrap Up Report on Clinical Trials for Cannabis-Derived Drugs by March-End
February 26, 2021
- Key Panel Gives Thumbs-Up to Teijin’s Osteoporosis Med, JCR’s Hunter Syndrome Drug and More
February 26, 2021
- Japan Might Ease Temperature Requirements for Pfizer Vaccine
February 26, 2021
- MHLW Panel Shelves Decision on Bayer’s Heart Failure Med Vericiguat
February 26, 2021
- CSL Plans Export of 2 Surplus Human Immunoglobulin Products
February 26, 2021
- 17,888 Doses of COVID-19 Vaccine Given in Japan as of Feb. 24
February 25, 2021
- Nichi-Iko Likely to Face Biz Suspension Order over Spate of Recalls
February 25, 2021
- MHLW Approves Add’l Use for Thaled, Bavencio and More
February 25, 2021
- 10,000 COVID-19 Patients Received Avigan in Observational Studies: Govt
February 25, 2021
- MHLW Formally Adopts GS1 Codes for Electronic Package Inserts; Rule to Take Effect August 1
February 25, 2021
- Japan to Start Elderly Vaccine Rollout from April 12: Minister
February 25, 2021
- MHLW to Revise Dyslipidemia Drug Development Guideline for 1st Time in 30 Years
February 25, 2021
- 4 APIs/9 Products Excluded from Kobayashi Kako Biz Suspension for Medical Needs
February 24, 2021
- MHLW Not Discussing Single-Dose Use of COVID-19 Vaccine: Minister
February 24, 2021
- Incyte’s Pemigatinib Clears PAFSC, March Approval Likely
February 24, 2021
- LDP COVID-19 Project Team to Compile Proposal on Single Vaccine Dose
February 24, 2021
- Orphan Status Granted to Novo’s Concizumab, Eisai’s E7090 and More
February 24, 2021
- LDP to Set Up Project Team to Strengthen Pharma Sector, Eyes Proposal in May
February 22, 2021
- Whether to Get COVID-19 Vaccines Up to Individuals to Decide: Govt
February 22, 2021
- First Possible Adverse Reactions from Pfizer Vaccine Reported in Japan
February 22, 2021
ページ
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
By managing personal bias during the interview process, hiring managers can significantly improve their hit rate placing winning candidates. The trouble is, it’s easier said than done. It’s only natural we tend to like people we can relate to, people…